Y. Bolshan, R.A. Batey / Tetrahedron 66 (2010) 5283–5294
5291
EtOAc/hexanes/Et3N 33:66:1); 1H NMR (300 MHz, CDCl3)
d
7.47 (dd,
146.6, 133.8, 132.2, 130.8, 128.9, 124.6, 122.1, 116.1, 32.0, 29.7, 22.4,
14.1; MS (EI) m/z (rel intensity) 76 (27), 104 (17), 150 (100), 205 (18),
248 (14); HRMS (EI) m/z calcd for C13H16N2O3 (Mþ) 248.1161, found
248.1155.
J¼7.0, 2.0 Hz,1H), 7.31 (ddd, J¼9.0, 6.5, 2.0 Hz,1H), 7.24 (d, J¼4.5 Hz,
1H), 6.55 (d, J¼9.0 Hz, 1H), 6.19 (dd, J¼6.0, 6.0 Hz, 1H), 5.79 (dt,
J¼14.5, 7.0 Hz, 1H), 2.18–2.25 (m, 2H), 1.41–1.51 (m, 4H), 0.92 (t,
J¼7.0 Hz, 3H); 13C NMR (75 MHz, CDCl3)
d 161.7, 140.0, 134.0, 126.9,
123.6, 121.4, 106.5, 31.6, 29.9, 22.4, 14.0.
4.4.8. 4-Chloro-trans-N-hex-1-enyl-benzamide (3i). Synthesized by
method B. Isolated as colorless crystals (79 mg, 66%): mp¼110–
111 ꢀC; crude product was purified by silica gel column chroma-
4.4.3. trans-1-Hex-1-enyl-1H-indole-2,3-dione (3c)28. Synthesized
by method A. Isolated as red crystals (94 mg, 82%); crude product
was purified by silica gel column chromatography (eluting with
tography (eluting with EtOAc/hexanes/Et3N 20:80:1); IR (neat)
3318, 2967, 2928, 2473, 1679, 1631, 1594, 1529, 1486, 954 cmꢂ1; 1H
NMR (400 MHz, acetone-d6)
n
EtOAc/hexanes/Et3N 25:75:1); IR (KBr pellet)
n
3454, 2923, 1732,
d
9.47 (d, J¼7.0 Hz, NH), 7.94 (m, 2H),
1608, 1470, 1362, 1324, 1181, 1095, 755 cmꢂ1
;
1H NMR (400 MHz,
7.49 (m, 2H), 6.94 (ddt, J¼14.5, 10.0, 1.5 Hz), 5.45 (dt, J¼14.5, 7.5 Hz),
CDCl3)
d 7.59–7.63 (m, 2H), 7.12–7.18 (m, 2H), 6.31–6.42 (m, 2H),
2.07 (m, 2H), 1.34 (m, 4H), 0.90 (J¼7.5 Hz); 13C NMR (125 MHz,
2.20–2.25 (m, 2H), 1.40–1.50 (m, 4H), 0.94 (t, J¼7.0 Hz, 3H); 13C
acetone-d6) d 162.6, 137.0, 132.9, 129.1, 128.5, 123.5, 113.5, 32.1, 29.5,
NMR (100 MHz, CDCl3)
d
182.8, 157.2, 150.6, 138.5, 126.1, 125.6,
21.9, 13.3; MS (EI) m/z (rel intensity) 111 (20), 139 (100), 141 (30),
237 (18), 239 (6); HRMS (EI) m/z calcd for C13H16NOCl (Mþ)
237.0920, found 237.0925.
124.4, 118.7, 117.9, 111.1, 31.7, 30.7, 22.4, 14.1; MS (EI) m/z (rel in-
tensity) 77 (28), 130 (19), 145 (100), 158 (70), 229 (46); HRMS (EI)
m/z calcd for C14H15NO2 (Mþ) 229.1102, found 229.1105.
4.4.9. 2-Chloro-trans-N-hex-1-enyl-benzamide (3j). Synthesized by
method B. Isolated as colorless crystals (85 mg, 71%): mp¼54–
56 ꢀC; crude product was purified by silica gel column chroma-
4.4.4. trans-3-Hex-1-enyl-oxazolidin-2-one (3d). Synthesized by
method B. Isolated as a colorless oil (82 mg, 97%); crude product
was purified by silica gel column chromatography (eluting with
tography (eluting with EtOAc/hexanes/Et3N 25:75:1); IR (neat)
3277, 3081, 2965, 2934, 1650, 1592, 1530, 1430, 953, 744 cmꢂ1 1H
NMR (400 MHz, acetone-d6)
n
EtOAc/hexanes/Et3N 50:50:1); IR (thin film)
1669, 1416, 1247, 1289, 1082, 943, 755 cmꢂ1
CDCl3)
6.63 (d, J¼14.5 Hz, 1H), 4.82 (dt, J¼14.5, 7.0 Hz, 1H), 4.42 (t,
n
2924, 2362, 1751,
;
;
1H NMR (300 MHz,
d
9.24 (d, J¼6.0 Hz, NH), 7.50–7.36 (m,
d
4H), 6.89 (ddt, J¼14.5, 10.0, 1.5 Hz, 1H), 5.42 (dt, J¼14.5, 7.0 Hz, 1H),
J¼8.0 Hz, 2H), 3.69 (t, J¼8.0 Hz, 2H), 2.03–2.10 (m, 2H), 1.23–1.43
2.12–2.05 (m, 2H),1.41–1.33 (m, 4H), 0.92 (t, J¼3.5 Hz, 3H); 13C NMR
(m, 4H), 0.90 (t, J¼7.0 Hz, 3H); 13C NMR (75 MHz, CDCl3)
d
155.7,
(125 MHz, acetone-d6) d 163.4, 136.4, 130.7, 129.8, 129.1, 127.0,
124.0, 111.6, 62.3, 42.8, 32.4, 29.6, 22.2, 14.1; MS (EI) m/z (rel in-
tensity) 100 (100), 126 (29), 170 (70), 192 (49); HRMS (EI) m/z calcd
for C9H15NO2 (Mþ) 189.0793, found 189.0793.
122.9, 122.8, 113.6, 32.0, 29.4, 21.9, 13.3; MS (EI) m/z (rel intensity)
111 (18), 139 (100), 141 (30), 237 (12), 239 (4); HRMS (EI) m/z calcd
for C13H16NOCl (Mþ) 237.0920, found 237.0920.
4.4.5. trans-N-Hex-1-enyl-benzamide (3f). Synthesized by method
B. Isolated as colorless crystals (83 mg, 81%); crude product was
purified by silica gel column chromatography (eluting with EtOAc/
4.4.10. 2,6-Dichloro-trans-N-hex-1-enyl-benzamide (3k). Synthe-
sized by method B. Isolated as colorless crystals (95 mg, 70%):
mp¼178–179 ꢀC; crude product was purified by silica gel column
chromatography (eluting with EtOAc/hexanes/Et3N 25:75:1); IR
hexanes/Et3N 20:80:1); IR (thin film)
n
3278, 3025, 2923, 1651,
1543, 1423, 1323, 1024, 946, 707 cmꢂ1
;
1H NMR (300 MHz, CDCl3)
(neat)
n 3252, 2928, 1652, 1548, 1432, 1317, 1119, 962, 800,
d
7.85–7.88 (m, 1H; NH), 7.79–7.84 (m, 2H), 7.50 (t, J¼7.5 Hz, 1H),
773 cmꢂ1; 1H NMR (400 MHz, acetone-d6)
d
9.39 (d, J¼7.0 Hz, NH),
7.41 (dd, J¼7.5, 7.5 Hz, 2H), 6.90–6.99 (m, 1H), 5.32 (dt, J¼14.5,
7.0 Hz, 1H), 2.04–2.10 (m, 2H), 1.29–1.42 (m, 4H), 0.90 (t, J¼7.0 Hz,
7.44–7.42 (m, 3H), 6.88 (ddt, J¼14.5, 10.0, 1.5 Hz), 5.41 (dt, J¼14.5,
7.0 Hz), 2.12–2.05 (m, 2H), 1.42–1.35 (m, 4H), 0.94–0.90 (m, 3H); 13C
3H); 13C NMR (75 MHz, CDCl3)
d
164.5, 134.1, 131.9, 128.8, 127.2,
NMR (125 MHz, acetone-d6) d 160.8, 136.3, 131.9, 131.0, 128.0, 122.5,
123.0, 114.6, 32.2, 29.7, 22.3, 14.1; MS (EI) m/z (rel intensity) 105
(100), 106 (7), 204 (4), 226 (17); HRMS (EI) m/z calcd for C13H18NO
(Mþþ1) 204.1382, found 204.1374.
114.2, 32.0, 29.4, 22.0, 13.3; MS (EI) m/z (rel intensity) 173 (100), 175
(70), 190 (28), 271 (12), 273 (7); HRMS (EI) m/z calcd for
C13H15NOCl2 (Mþ) 271.0531, found 271.0534.
4.4.6. trans-N-Hex-1-enyl-4-nitro-benzamide (3g). Synthesized by
method B. Isolated as yellow crystals (106 mg, 85%): mp¼124–
125 ꢀC; crude product was purified by silica gel column chroma-
tography (eluting with EtOAc/hexanes/Et3N 20:80:1); IR (KBr pel-
4.4.11. trans-N-Hex-1-enyl-3-trifluoromethyl-benzamide
(3l). Synthesized by method B. Isolated as colorless crystals (90 mg,
66%): mp¼43–44 ꢀC; crude product was purified by silica gel col-
umn chromatography (eluting with EtOAc/hexanes/Et3N 20:80:1);
let)
n
3296, 2928, 2420, 1641, 1599, 1515, 1297, 953, 866, 844,
IR (neat)
n 3259, 3202, 2963, 1644, 1544, 1348, 1320, 1163, 1120,
708 cmꢂ1; 1H NMR (300 MHz, CDCl3)
d
8.27 (d, J¼8.5 Hz, 2H), 8.07
920 cmꢂ1; 1H NMR (400 MHz, acetone-d6)
d
9.67 (d, J¼7.5 Hz, NH),
(d, J¼10.0 Hz, 1H; NH), 7.98 (d, J¼8.5 Hz, 2H), 6.91 (dd, J¼14.0,
10.0 Hz, 1H), 5.43 (dt, 1H, J¼14.0, 7.0 Hz, 1H), 2.05–2.12 (m, 2H),
1.26–1.43 (m, 4H), 0.90 (t, J¼7.0 Hz, 3H); 13C NMR (75 MHz, CDCl3)
8.24–8.21 (m, 2H), 7.88 (d, J¼8.0 Hz, 1H), 7.73 (t, J¼8.0 Hz, 1H), 7.0
(ddt, J¼14.5, 10.0, 1.5 Hz, 1H), 5.5 (dt, J¼14.5, 7.0 Hz, 1H), 2.11–2.04
(m, 2H), 1.40–1.28 (m, 4H), 0.90 (t, J¼7.0 Hz, 3H); 13C NMR
d
162.5, 149.9, 139.7, 128.5, 124.1, 122.5, 116.6, 32.1, 29.7, 22.3, 14.1;
(125 MHz, acetone-d6)
d
162.2, 135.2, 131.2, 129.9 (q, J¼32.5 Hz),
MS (EI) m/z (rel intensity) 104 (25), 150 (100), 167 (25), 205 (34),
248 (12); HRMS (EI) m/z calcd for C13H16N2O3 (Mþ) 248.1161, found
248.1167.
129.5, 127.9 (q, J¼3.5 Hz), 124.1 (q, J¼271.5 Hz), 124.0 (q, J¼4.0 Hz),
123.4, 114.1, 32.1, 29.5, 21.9 ,13.1; MS (EI) m/z (rel intensity) 145 (28),
173 (100), 190 (18), 228 (15), 271 (9); HRMS (EI) m/z calcd for
C14H16F3NO (Mþ) 271.1195, found 271.1184.
4.4.7. trans-N-Hex-1-enyl-2-nitro-benzamide (3h). Synthesized by
method B. Isolated as yellow crystals (89 mg, 72%); crude product
was purified by silica gel column chromatography (eluting with
4.4.12. trans-N-Hex-1-enyl-4-methoxy-benzamide (3m). Synthe-
sized by method B. Isolated as colorless crystals (65 mg, 56%); crude
product was purified by silica gel column chromatography (eluting
with EtOAc/hexanes/Et3N 25:75:1); 1H NMR (300 MHz, CDCl3)
EtOAc/hexanes/Et3N 50:50:1); 1H NMR (300 MHz, CDCl3)
d 8.13 (d,
J¼10.0 Hz, 1H, NH), 7.91 (d, J¼8.0 Hz, 1H), 7.57 (dd, J¼7.5, 7.5 Hz,
1H), 7.47 (dd, J¼7.5, 7.5 Hz, 1H), 7.39 (d, J¼7.0 Hz, 1H), 6.68 (dd,
J¼14.0, 10.0 Hz, 1H), 5.21 (dt, J¼14.0, 7.0 Hz, 1H), 1.29–2.00 (m, 2H),
d
7.95 (d, J¼10.0 Hz,1H; NH), 7.76 (d, J¼9.0 Hz, 2H), 6.94 (dd, J¼14.0,
10.0 Hz,1H), 6.87 (d, J¼9.0 Hz, 2H), 5.29 (dt, J¼14.0, 7.0 Hz,1H), 3.81
(s, 3H), 2.00–2.07 (m, 2H), 1.32–1.39 (m, 4H), 0.88 (t, J¼7.0 Hz, 3H);
1.31 (s, 4H), 0.89 (d, J¼7.0 Hz, 3H); 13C NMR (75 MHz, CDCl3)
d 163.5,